Introduction
Paroxysmal kinesigenic dyskinesia (PKD) is the most common paroxysmal movement disorder, characterized by recurrent attacks of dyskinesia which is triggered by sudden voluntary movement. These attacks are usually brief, and could last from a few seconds to one minute, and they occur multiple times per day [1, 2] .
The scanned brain image and electroencephalography (EEG) of such patients are usually normal [3] , however, mutations of proline-rich transmembrane protein 2 (PRRT2) have recently been identified in PKD [4] . The most common drugs used for PKD treatment in the clinical at present are carbamazepine (CBZ) and oxcarbazepine (OXC) [5] . While lamotrigine (LTG) is also effective based on a few sporadic case reports [6] , but clinical researches that proves LTG's effectiveness is very limited.
The study reported herein is designed as an evaluation of the possibility of LTG monotherapy for PKD in children. The goal is to seek how many children would become attack free, the amount of drug which is effective, and whether there is genetic or behavior predictors for response to LTG.
was registered in Chinese Clinical Trial Registry (ChiCTR-OPC-15006294).
Patients
Eighteen non-blood related patients <16 years old were enrolled. All the patients were of Han Chinese descents and diagnosed with PKD according to the clinical diagnostic criteria of Bruno in 2004 [7] .
Identified kinesigenic trigger for the attacks. Short duration of attacks (<1 min). No loss of consciousness and no pain during attacks; Exclusion of other organic diseases and normal neurologic examination results. Control of attacks with an antiepileptic drug such as carbamazepine or phenytoin, if tried. Age at onset between 1 and 20 years if no family history of PKD. Age criteria might not be as important in the familial cases.
Procedures and assessments
Every patient enrolled received a video-EEG more than 4 h of duration during which each patient was allowed to fall asleep naturally. When awake the patient is asked to do his/her own trigger action such as sudden movement to induce the attack.
LTG was titrated and given in escalation dose. The dosage started from 6.25 mg per day, and gradually increased every week until attacks were controlled. Patients entered the maintenance dose phase upon reaching their effective dosage, by being attack free at two consecutive outpatient visits. They were followed up in the Child Neurology Department from January 2008 to December 2014. The data were collected and analyzed with simple correlation, t-test or F test in SPSS 17.0. Statistical significance was defined as P < 0.05.
Results
Eighteen patients were enrolled in this study, 13 males and 5 females; the mean age of onset was 7.89 AE 3.03 years (range 2-12). According to the parents, all attack-durations were less than 30 s, and the frequency ranged from less than 1 time per day to more than 10 times per day. In our research, top three triggers were sudden movement (18/18), intention to move (8/18) and stress (2/ 18). Three patients had failed trial of OXC, and the others had no past drug history. All the patients had normal video-EEGs and brain CT or MRI scans. Fourteen patients had a positive family history and 4 patients were apparently sporadic cases. Family history was considered positive if a patient had at least one affected relative within three generations. Mutations of PRRT2 gene were found in 15 patients (c.649dupC in 12 cases, c.291delC in 3 cases). Seven patients had experienced febrile convulsions, focal seizure or afebrile infantile seizure before. The mean period of following up was 39.2 AE 16.9 months (range 9-73). Demographics and clinical characteristics were presented in Table 1 . The initial dosage of 6.25 mg was same for all participants (range 0.104-0.568 mg/kg), and gradually increased every week. By the end of the 4th week, all (18/18) patients were attack free. At maintenance dose phase, mean serum concentration was 0.87 AE 0.33 mg/ml (range 0.22-1.42), and mean daily dosage was 26.39 AE 13.31 mg (range 6.25-50), no statistical differences were found in our study between young children and older ones or their disparity in weights or ages of onset, see Tables 2 and 3 .
During maintenance dose phase in follow up, 89% (16/18) patients remained attack free. Most patients did not require additional drug during follow up except two (case 8 and 17) whose attacks relapsed when they entered puberty at 10 and 9 years old respectively. Three patients (case 3, 13 and 15) had relapses because of non-compliance to the therapy, but they became attack free as soon as they re-started the medicine. These factors may affect the amount of effective dosage such as sex, family history, PRRT2 mutations, history of epileptic seizures, trigger causes, duration of attack and frequency of attack, but none had statistical significance, see Table 4 . Rash and pruritus were seen on trunks of 2 patients, both temporary and mild, but it is not certain to be related to LTG. No patients withdrew at any point from the study, see Table 2 .
Discussion
PKD is the most common form of paroxysmal dyskinesia, patients always can describe their feeling about the attacks. The typical characters of the attack are existence of consciousness and clear triggers. Most patients have more than one triggers, according to our study sudden movement, intention to move and stress are probably the top three triggers. It is believed PKD patients have benign course of the disease and the tendency to have decreased attack frequency with age, but effective control of PKD is still very important given its potential impact on children's safety as well as psychosocial function during a critical period of development.
In recent years, an important finding that is PRRT2 mutations has a close association with PKD, benign familial infantile epilepsy (BFIE), infantile convulsions with choreoathetosis (ICCA) syndrome and families with hemiplegic migraine (HM) [8] [9] [10] [11] , and it improves accuracy of the diagnosis for these diseases by a genetic test. The research of possible associations between this mutation with other seizure disorders like convulsions with gastroenteritis (CwG) and benign familial neonatal epilepsy (BFNE) is still on the way. Although PRRT2 is a largely uncharacterized protein, it is expressed in the brain and has been demonstrated to interact with SNAP-25, a component of the molecular machinery involved in the release of neurotransmitters at the presynaptic membrane [11] , it makes sense that PKD presents like a channelopathy because the release of neurotransmitter is triggered by the influx of some ions resulting from an action potential. More importantly, it had reported by Hong-Fu Li and his colleagues that PRRT2 mutation carriers tended to respond to low-dose CBZ, whereas 94% of non-PRRT2 mutation carriers did not have a full response to CBZ, even after the dosage had been increased [12] .
In present clinical practice, antiepileptic drugs like CBZ and OXC are the first choice for treatment of PKD, and the sodium ion channel blockers have been suggested [5, 13] . In general patients typically respond well to low dosage of above drugs which can reduce attacks beyond 90% and the attack-free percentage beyond 50%. But still a few patients respond poor, or can not continue for adverse events, like rash, cognitive and behavioral change [14] . LTG has a similar pharmacologic function as CBZ, both of them sodium ion channel blockers. So is it possible it has similar efficacy or less adverse effects for PKD therapy? A few sporadic case reports supported this point [6] , however clinical experience available is very limited, and no studies proposed a specific dose usage.
In our study we accumulated experience on LTG therapy for PKD by demonstrating that efficacy was seen at the 4th week off therapy, the attack-free percentage of our patients in LTG monotherapy was 100% (18/18), it was much higher than that reported in CBZ monotherapy. Given evidences that slowed titration of LTG reduced the risk of serious rash [15] , we elected to mimic clinical practice. We found the therapeutic dosage for PKD was much lower, even though a higher dosage should be used in patients at puberty, than that for epileptic seizure control. Moreover, the effective amount of dosage seems to have little correlation with age of onset, age or weight. We analyzed other clinical features as well including sex, trigger causes, duration of attack, PRRT2 mutations, history of epileptic seizures and family history, but none of the above was statistically related with the effective amount of dosage. Our study showed LTG was more effective than CBZ for PKD in non-PRRT2 mutation carriers [12] , but our sample of 3 parents were too small. LTG was generally well tolerated in our study, no cases of serious rash were reported, and no patients had intellectual impairment or decline of school performance during follow-up, thus suggesting LTG may have less adverse effects than CBZ or OXC. Three patients relapsed due to non-compliance to the treatment, which suggested that the therapy should be continued for a long time. More exploratory studies should be done to find concrete evidence to decide whether LTG should be preferred over CBZ and OXC.
Conclusions
LTG at a mean dosage of 26.4 mg (range 6.25-50) daily is effective and well tolerated for PKD in children, therefore it is an important therapeutic option for pediatric neurologist.
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